AOD-9604

Scientific identity: AOD-9604 is a 16-amino-acid synthetic peptide derived from the C-terminal lipolytic domain of human growth hormone — specifically residues 176–191 of the mature hGH sequence — with a tyrosine residue appended at the N-terminus (Tyr-hGH176–191). The Cys182–Cys189 disulfide bridge present in native hGH is preserved in AOD-9604, forming a constrained cyclic structure within the peptide that is considered relevant to its biological activity in experimental systems. This region of hGH has been identified in research as distinct from the growth-promoting N-terminal domain and has been examined independently in relation to lipolysis-related signaling in adipocyte models.

Peptide class: Synthetic human growth hormone C-terminal fragment; lipolytic domain peptide; hGH(176–191) analogue with N-terminal tyrosine addition.

Primary research context: Human growth hormone C-terminal lipolytic domain pharmacology; adipocyte lipolysis signaling; growth hormone fragment biology independent of IGF-1 axis stimulation.

Research areas: Growth hormone fragment pharmacology, adipocyte biology, lipolysis-related signaling research, hGH domain structure-activity research, growth hormone receptor biology.

Available quantities: 5mg and 10mg per vial.

Purity: Greater than 99%, confirmed by HPLC and LC-MS analysis at the batch level.

Analytical documentation: A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability.

Research-use classification: For laboratory research use only. Not for human or veterinary use, clinical diagnostics, or any in-vivo application in humans.

hGH Domain Structure and the Lipolytic Fragment

Full-length human growth hormone (hGH, 191 amino acids) exerts its biological effects through multiple structural domains with distinct receptor interactions. The N-terminal region — particularly site 1 — mediates high-affinity binding to the growth hormone receptor (GHR) and is responsible for the growth-promoting, protein anabolic, and IGF-1-stimulating effects of hGH. The C-terminal region, encompassing approximately residues 177–191, has been studied as a structurally distinct domain with proposed lipolytic activity independent of the N-terminal growth-promoting domain. AOD-9604 is a synthetic research tool derived from this C-terminal region, used to examine its pharmacological properties in isolation from the full-length hGH context.

Adipocyte Biology and Lipolysis Research

Cell-based research has examined AOD-9604 in adipocyte models — including 3T3-L1 cells — measuring lipolysis-related endpoints such as glycerol release, fatty acid liberation, and related metabolic parameters as indicators of lipase activity and fat mobilisation signaling. Animal studies have investigated AOD-9604 administration in diet-induced obese rodent models, examining body composition and adipose tissue parameters. These are preclinical findings in defined experimental systems and cannot be directly extrapolated to human outcomes.

Distinction from Full-Length hGH

A key research question examined in the AOD-9604 literature is whether the C-terminal hGH fragment retains lipolytic activity while lacking the growth-promoting, IGF-1-stimulating, and insulin-antagonising properties of full-length hGH. Published research has characterised AOD-9604 in experimental systems designed to assess GH receptor binding, IGF-1 secretion, and growth parameters alongside lipolytic endpoints. These studies have generally reported that AOD-9604 does not stimulate IGF-1 production or linear growth in animal models at doses producing lipolytic effects — findings that represent preclinical observations in specific experimental systems rather than established human pharmacological properties.

Human Clinical Research and Regulatory Status

AOD-9604 was investigated in human clinical trials for obesity management under pharmaceutical development, with studies examining safety, pharmacokinetics, and efficacy endpoints in overweight and obese adult populations. These trials did not result in regulatory approval for an obesity indication. AOD-9604 does not hold FDA, EMA, or TGA approval for any therapeutic indication. Clinical findings from this development programme concern pharmaceutical-grade formulations under regulated trial conditions and do not establish the safety, efficacy, or bioavailability of the Longevia Research research vial.

Reliable research begins with accurately characterised material. For a 16-amino-acid disulfide-containing peptide such as AOD-9604, that means confirming sequence integrity, disulfide bridge formation, and purity at the batch level — because reduced (ring-open) AOD-9604 lacking the Cys–Cys disulfide bridge is a structurally distinct compound with a different conformation and potentially different receptor engagement profile that can confound lipolysis assays and growth hormone fragment binding studies.

Purity assessment: Each production lot is characterised to greater than 99% purity by high-performance liquid chromatography (HPLC). Chromatographic purity data is reported on the batch Certificate of Analysis.

Identity confirmation: Peptide identity and disulfide bridge integrity are confirmed by mass spectrometry (LC-MS), providing molecular-weight verification consistent with the disulfide-bonded form. HPLC and LC-MS data together confirm that the material supplied corresponds to the labelled compound at the labelled purity.

Batch traceability and Certificate of Analysis: Every vial of AOD-9604 5mg and 10mg is traceable to a specific production lot. A batch-specific Certificate of Analysis is accessible directly on the Longevia Research website, covering purity, identity, and lot information. Researchers evaluating this material for assay work are encouraged to review the current batch documentation before use, since analytical specifications are applied at the lot level.

Handling: This material should be handled by qualified personnel using appropriate laboratory technique and personal protective equipment, consistent with institutional protocols for research-grade disulfide-containing synthetic peptides.

Longevia Research supplies AOD-9604 5mg and 10mg for laboratory and in-vitro research use only. The product is intended for use by qualified researchers and trained laboratory personnel in appropriate controlled research environments.

AOD-9604 is a synthetic research peptide supplied strictly as a research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. AOD-9604 does not hold FDA, EMA, or TGA approval for any therapeutic indication. Prior human clinical investigation of AOD-9604 for obesity did not result in regulatory approval, and no approval applies to the Longevia Research research vial, which is not a pharmaceutical product and has not been evaluated by any regulatory authority for safety or efficacy in this formulation.

Longevia provides no dosing instructions, administration guidance, treatment protocols, or reconstitution recommendations for this compound. The scientific literature summarised on this product page describes experimental observations in defined cell-based, animal, and human clinical research systems. Those findings are not medical claims and should not be interpreted as evidence of human efficacy, human safety, or fitness for any clinical application from this product.

The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations. By purchasing this product, the buyer confirms that it will be used solely for legitimate laboratory research purposes by qualified personnel, and that its acquisition and intended use comply with applicable laws in the buyer's jurisdiction.